Amy Beth Vanduyn Sells 639 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 639 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $14,288.04. Following the completion of the sale, the senior vice president owned 111,840 shares in the company, valued at $2,500,742.40. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, September 16th, Amy Beth Vanduyn sold 1,762 shares of Phreesia stock. The stock was sold at an average price of $23.28, for a total value of $41,019.36.

Phreesia Price Performance

NYSE:PHR opened at $23.42 on Thursday. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.40 billion, a P/E ratio of -55.76 and a beta of 0.68. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $32.76. The business’s 50-day moving average is $25.82 and its 200 day moving average is $25.95.

Phreesia (NYSE:PHR) last posted its earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.08. The company had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. On average, equities research analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PHR has been the topic of a number of research analyst reports. Needham & Company LLC boosted their target price on Phreesia from $29.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Piper Sandler boosted their target price on Phreesia from $33.00 to $34.00 and gave the stock an “overweight” rating in a research report on Friday, September 5th. Mizuho started coverage on Phreesia in a research report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 target price on the stock. Truist Financial upped their price objective on Phreesia from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, September 5th. Finally, Citigroup restated an “outperform” rating on shares of Phreesia in a research report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.85.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. Raymond James Financial Inc. grew its stake in shares of Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after buying an additional 375 shares during the last quarter. Diversified Trust Co grew its stake in shares of Phreesia by 1.0% during the second quarter. Diversified Trust Co now owns 45,042 shares of the company’s stock valued at $1,282,000 after buying an additional 426 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Phreesia by 2.8% during the second quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock valued at $569,000 after buying an additional 540 shares during the last quarter. Arcadia Investment Management Corp MI grew its stake in shares of Phreesia by 0.7% during the first quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company’s stock valued at $2,371,000 after buying an additional 615 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Phreesia by 9.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company’s stock valued at $251,000 after buying an additional 792 shares during the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.